Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

From The Quarterly Conference Calls

Executive Summary

Geneva Augmentin generic reserve: Geneva's generic amoxicillin/clavulanate earnings are being placed in a reserve in the event the company loses GlaxoSmithKline's appeal of the Augmentin patent lawsuit, Novartis CEO Daniel Vasella said July 22. "We will book sales, but we will not book the earnings out of this product but put them in a reserve," the exec said. "The additional exposure should we - against all odds - lose the appeal next year, would be an amount which we can digest, I would say, rather easily." GSK is appealing a May 22 ruling in Geneva's favor; a decision could come as early as January (1"The Pink Sheet" May 27, p. 20). Geneva launched amoxicillin generics in June...

You may also be interested in...



Augmentin patent ruling

Four generic versions of Augmentin will remain on the market following a Federal Circuit decision that affirmed a ruling invalidating GlaxoSmithKline's patents for nonstatutory double patenting. Novartis' Geneva division launched the first generic version of the antibiotic in June 2002. Ranbaxy, Teva and Novartis' Lek division also market generic amoxicillin/clavulanate. Novartis has been placing Geneva's earnings from the generic in reserve in case the company lost the appeal (1"The Pink Sheet" Aug. 5, 2002, p. 35)...

Augmentin patent ruling

Four generic versions of Augmentin will remain on the market following a Federal Circuit decision that affirmed a ruling invalidating GlaxoSmithKline's patents for nonstatutory double patenting. Novartis' Geneva division launched the first generic version of the antibiotic in June 2002. Ranbaxy, Teva and Novartis' Lek division also market generic amoxicillin/clavulanate. Novartis has been placing Geneva's earnings from the generic in reserve in case the company lost the appeal (1"The Pink Sheet" Aug. 5, 2002, p. 35)...

J&J Topamax Letter Recommends Monitoring For Decreased Sweating

A warning added to Johnson & Johnson's anti-convulsant Topamax (topiramate) is in line with a label revision for Elan's anti-convulsant Zonegran stating that patients should be closely monitored for decreased sweating and increased body temperature

Related Content

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel